Nivolumab for advanced melanoma: pretreatment prognostic factors and early outcome markers during therapy

BACKGROUND: An anti-programmed cell death protein 1 monoclonal antibody, nivolumab, is one of the most effective drugs for advanced melanoma. Tumor cell-derived or immune cell-derived markers and clinical predictors such as serum lactate dehydrogenase (LDH) and cutaneous adverse events, have already...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Oncotarget
Egile Nagusiak: Nakamura, Yoshio, Kitano, Shigehisa, Takahashi, Akira, Tsutsumida, Arata, Namikawa, Kenjiro, Tanese, Keiji, Abe, Takayuki, Funakoshi, Takeru, Yamamoto, Noboru, Amagai, Masayuki, Yamazaki, Naoya
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Impact Journals LLC 2016
Gaiak:
Research Paper
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5363594/
https://ncbi.nlm.nih.gov/pubmed/27764805
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.12677
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak